Denosumab as a treatment alternative for central giant cell granuloma: a long-term retrospective cohort study

Publication date: Available online 21 September 2017
Source:Journal of Oral and Maxillofacial Surgery
Author(s): Marius Bredell, Tamara Rordorf, Sabine Kroiss, Martin Rücker, Daniel Fritz Zweifel, Claudio Rostetter
PurposeGiant cell granuloma of the jaw is a rare disease with a high morbidity. Various treatment options have been discussed in the past. Since 2010, a pharmaceutical therapy with denosumab seems to be successful for giant cell tumors of the femur. The investigators hypothesized the equally successful use of denosumab for giant cell granulomas of the jaws.MethodIn the current retrospective cohort study five patients with large giant cell granulomas of the jaws were treated with denosumab on a follow-up of 25 to 49 months. Frequent clinical and a radiological follow up was performed and systematically analysed.ResultsAll patients showed curative treatment response and complete metabolic resolution of the giant cell granulomas under treatment with denosumab.ConclusionA brief review of the relevant literature and a detailed evaluation of the current cases lead us the conclusion that denosumab therapy should be considered as a therapeutic option in large CGCG's of the jaws. The results of this study suggest a successful treatment option. Treatment length of not shorter than 12 months is recommended and monitoring of treatment response can be well managed by PET CT or MRI.



http://ift.tt/2xVG6iX